Related Experiment Video
Updated: May 17, 2026

Designing Porous Silicon Films as Carriers of Nerve Growth Factor
Published on: January 25, 2019
Mechanisms of antiproliferative drug release from bioresorbable porous structures
Amir Kraitzer1, David Alperstein, Yoel Kloog
1Department of Biomedical Engineering, Tel-Aviv University, Tel-Aviv 69978, Israel.
Abstract:
Restenosis (renarrowing of the blood vessel wall) and cancer are two different pathologies that have drawn extensive research attention over the years. Antiproliferative drugs such as paclitaxel inhibit cell proliferation and are therefore effective in the treatment of cancer as well as neointimal hyperplasia, which is known to be the main cause of restenosis. Antiproliferative drugs are highly hydrophobic and their release from porous biodegradable structures is therefore advantageous. The release profiles of four antiproliferative drugs from highly porous polymeric structures were studied in this study in light of the physical properties of both the host polymers and the drug molecules, and a qualitative model was developed. The chemical structure of the polymer chain directly affects the drug release profile through water uptake in the early stages or degradation and erosion in later stages. It also affects the release profile indirectly, through the polymer's 3D porous structure. However, this effect is minor. The drug volume and molecular area dominantly affect its diffusion rate from the 3D porous structure and the drug's solubility parameter compared with that of the host polymer has some effect on the drug release profile. This model can also be used to describe release mechanisms of other hydrophobic drugs from porous structures.
Related Concept Videos
Modified-Release Drug Delivery Systems: Rate-Programmed II
Modified-Release Drug Delivery Systems: Stimuli-Activated
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Oral Drug Delivery Systems: Delayed-Release Systems
Modified-Release Drug Delivery Systems: Rate-Programmed I
Oral Drug Delivery Systems: Continuous-Release Systems

